Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

• Main Authors: Elke L. M. ter Haar (Author), Juul M. P. A. van den Reek (Author), Kristian Gaarn Du Jardin (Author), Almudena Barbero-Castillo (Author), Elke M. G. J. de Jong (Author), Satish F. K. Lubeek (Author)
• Format: Book
• Published: Medical Journals Sweden, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among younger and older patients with psoriasis (< 65/≥ 65 years) in a post hoc analysis of 2 phase III trials (reSURFACE1/2, n = 1,862). Tildrakizu...